SCHEMBL29333362

SCHEMBL29333362

CC(C)C1CCC(=S)N(C)C1

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23107036 0.75 SRD5A1 (0.44) SRD5A1
SCHEMBL24456727 0.75 SRD5A1 (0.44) SRD5A1
SCHEMBL7875670 0.75 SRD5A1 (0.44) SRD5A1
SCHEMBL1956434 0.71
SCHEMBL14787450 0.67 SRD5A1 (0.42) SRD5A1
SCHEMBL24398720 0.64 ACE (0.38)
SCHEMBL19844790 0.62 KAT2B (0.31)
SCHEMBL19844781 0.62 KAT2B (0.31)
SCHEMBL19844783 0.62 KAT2B (0.31)
SCHEMBL19844776 0.62 KAT2B (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 SRD5A1 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.